PKO Investment Management Joint Stock Co Has $3.74 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• PKO Investment Management cut its stake in Regeneron by 56.7% in Q4, selling 6,350 shares and retaining 4,850 shares valued at about $3.744 million.
• Regeneron posted a stronger-than-expected Q1 (revenue +19%, EPS $9.47 vs. $8.91 est.) and announced a $3 billion share buyback, but shares fell amid mixed analyst reactions and some price-target downgrades.
• Insiders have been net sellers recently—3,774 shares (~$2.94 million) sold in the past 90 days, including a 1,638-share sale by Director Huda Z. Zoghbi—though insiders still hold about 7.02% of the company.

PKO Investment Management Joint Stock Co reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 56.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,850 shares of the biopharmaceutical company's stock after selling 6,350 shares during the quarter. PKO Investment Management Joint Stock Co's holdings in Regeneron Pharmaceuticals were worth $3,744,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. WPG Advisers LLC raised its stake in Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 25 shares in the last quarter. Board of the Pension Protection Fund acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $31,000. Salomon & Ludwin LLC acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth about $27,000. Torren Management LLC bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at about $38,000. Finally, FNY Investment Advisers LLC bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at about $38,000. Institutional investors own 83.31% of the company's stock.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported a stronger-than-expected Q1 (revenue up ~19%, EPS beat) and announced a $3 billion share buyback — fundamentals and the buyback are clear upside catalysts for shareholder value. Regeneron reports strong Q1 CY2026
• Positive Sentiment: Guggenheim raised its price target to $995 and retained a Buy — that implies sizable upside and supports sentiment among growth/value investors. Guggenheim raises REGN target to $995
• Neutral Sentiment: Zacks highlights REGN as a long-term value pick — supportive narrative for buy-and-hold investors but not an immediate price catalyst. Why Regeneron is a Top Value Stock
• Neutral Sentiment: Several banks trimmed price targets modestly (Barclays, Truist, Wells Fargo) but largely kept positive/market-weight ratings — suggests analysts revised models after Q1 details but remain constructive overall. Analyst PT changes after Q1
• Negative Sentiment: Royal Bank of Canada cut its target to $762 and moved to a "sector perform" stance — a more cautious view that likely weighed on intraday selling pressure. RBC lowers REGN target to $762
• Negative Sentiment: Coverage and model cuts followed the Q1 release despite the beat; investors focused on items such as a 10% drop in net income year-over-year (even as revenue rose), which may have trimmed near-term expectations. Regeneron Q1 2026 net income falls 10%
• Negative Sentiment: Market reaction: shares fell despite the beat — coverage (Seeking Alpha) points to investor disappointment or guidance/forward assumptions as the reason for the drop. That momentum explains today's weaker price action. Regeneron drops despite Q1 beat

Wall Street Analyst Weigh In

REGN has been the subject of a number of recent analyst reports. Evercore upped their price target on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an "outperform" rating in a report on Thursday, January 22nd. Truist Financial decreased their price objective on shares of Regeneron Pharmaceuticals from $801.00 to $796.00 and set a "buy" rating on the stock in a research note on Thursday. Zacks Research downgraded shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Friday, February 6th. Morgan Stanley upped their target price on Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the stock an "equal weight" rating in a research note on Friday, April 10th. Finally, Wells Fargo & Company reduced their target price on Regeneron Pharmaceuticals from $825.00 to $800.00 and set an "equal weight" rating on the stock in a report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $826.59.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Huda Y. Zoghbi sold 1,638 shares of the business's stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the sale, the director owned 1,703 shares in the company, valued at $1,330,604.99. The trade was a 49.03% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the transaction, the director owned 17,803 shares of the company's stock, valued at $13,860,169.59. This represents a 0.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 3,774 shares of company stock worth $2,942,738. Corporate insiders own 7.02% of the company's stock.

Regeneron Pharmaceuticals Stock Down 0.8%

REGN stock opened at $701.42 on Friday. The firm has a 50-day moving average price of $756.81 and a 200-day moving average price of $736.41. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11. The company has a current ratio of 3.57, a quick ratio of 3.39 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $74.15 billion, a P/E ratio of 17.09, a price-to-earnings-growth ratio of 1.61 and a beta of 0.30.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.91 by $0.56. The company had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm's revenue was up 19.0% on a year-over-year basis. During the same period in the previous year, the firm posted $8.22 EPS. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 36.05 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th will be issued a dividend of $0.94 per share. The ex-dividend date is Wednesday, May 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio is 9.16%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.